Data sourcesSEC Form 42h ago
House PTR2h ago
SEC 13F2h ago
Robinhood Chain2h ago
Public companyPRECISION BIOSCIENCES INC
DTILCIK 0001357874
Price$10.60
1 year+60.1%
Disclosed transactions29
Buys / sells1 / 4
Max Insider Score29
Connections with evidence7
DTIL · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 29 | FSFrankel StanleyDirector | DTILPRECISION BIOSCIENCES INC Open-market purchase | BUY | $6,000 1,000 sh | Sep 28, 2026 | Sep 30, 2026 |
| 3 | SJSmith J. JeffersonChief Research Officer | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 10.4K sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 3 | AMAmoroso MichaelDirector, President and CEO | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 8,888 sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 7 | AMAmoroso MichaelDirector, President and CEO | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 69.4K sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 3 | SDScimeca DarioGeneral Counsel and Secretary | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 1,978 sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 7 | KAKelly John AlexanderChief Financial Officer | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 26.6K sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 0 | KAKelly John AlexanderChief Financial Officer | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 3,888 sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 11 | KAKelly John AlexanderChief Financial Officer | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 13.9K sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 0 | SJSmith J. JeffersonChief Research Officer | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 10.4K sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 0 | SDScimeca DarioGeneral Counsel and Secretary | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 14.9K sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 7 | AMAmoroso MichaelDirector, President and CEO | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 37.1K sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 27 | AMAmoroso MichaelDirector, President and CEO | DTILPRECISION BIOSCIENCES INC Open-market sale · 10b5-1 plan | SELL | $145K 34.8K sh | Jan 22, 2026 | Jan 22, 2026 traded Jan 22, 2026 | +0d | SEC Form 4 | |
| 0 | SDScimeca DarioGeneral Counsel and Secretary | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 1,978 sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 0 | AMAmoroso MichaelDirector, President and CEO | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 69.4K sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 0 | SDScimeca DarioGeneral Counsel and Secretary | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 8,425 sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 0 | AMAmoroso MichaelDirector, President and CEO | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 8,888 sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 7 | SDScimeca DarioGeneral Counsel and Secretary | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 14.9K sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 0 | AMAmoroso MichaelDirector, President and CEO | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 37.1K sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 3 | KAKelly John AlexanderChief Financial Officer | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 13.9K sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 27 | KAKelly John AlexanderChief Financial Officer | DTILPRECISION BIOSCIENCES INC Open-market sale · 10b5-1 plan | SELL | $61K 15.2K sh | Jan 21, 2026 | Jan 22, 2026 traded Jan 21, 2026 | +1d | SEC Form 4 | |
| 0 | SJSmith J. JeffersonChief Research Officer | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 2,500 sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 3 | SJSmith J. JeffersonChief Research Officer | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 16.2K sh | Jan 21, 2026 | Jan 22, 2026 traded Jan 21, 2026 | +1d | SEC Form 4 | |
| 24 | SJSmith J. JeffersonChief Research Officer | DTILPRECISION BIOSCIENCES INC Open-market sale · 10b5-1 plan | SELL | $41K 10.2K sh | Jan 21, 2026 | Jan 22, 2026 traded Jan 21, 2026 | +1d | SEC Form 4 | |
| 7 | SDScimeca DarioGeneral Counsel and Secretary | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 8,425 sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 24 | SDScimeca DarioGeneral Counsel and Secretary | DTILPRECISION BIOSCIENCES INC Open-market sale · 10b5-1 plan | SELL | $36K 8,854 sh | Jan 21, 2026 | Jan 22, 2026 traded Jan 21, 2026 | +1d | SEC Form 4 | |
| 0 | KAKelly John AlexanderChief Financial Officer | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 26.6K sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 0 | SJSmith J. JeffersonChief Research Officer | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 2,500 sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 3 | KAKelly John AlexanderChief Financial Officer | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 3,888 sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 0 | SJSmith J. JeffersonChief Research Officer | DTILPRECISION BIOSCIENCES INC Option exercise · 10b5-1 plan | M | — 16.2K sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
Chief Financial Officer · Jan 22, 2026
Planned sales and 5% stakes
Form 144, 13D and 13G